The current study has demonstrated a relative reduction in vanadium‐induced neurotoxicity, as evidenced by improvements in neuronal pathology, neuro‐inflammatory injury, and various proteinopathies, including synucleinopathy, amyloid degeneration, and tau aggregation, following the cessation of vanadium exposure. The gene discussed is MAPT; the disease is synucleinopathy.